EP2240158A2 - Stabilisierte injizierbare pregabalin-formulierung - Google Patents

Stabilisierte injizierbare pregabalin-formulierung

Info

Publication number
EP2240158A2
EP2240158A2 EP08869815A EP08869815A EP2240158A2 EP 2240158 A2 EP2240158 A2 EP 2240158A2 EP 08869815 A EP08869815 A EP 08869815A EP 08869815 A EP08869815 A EP 08869815A EP 2240158 A2 EP2240158 A2 EP 2240158A2
Authority
EP
European Patent Office
Prior art keywords
formulation
pregabalin
injectable
present
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08869815A
Other languages
English (en)
French (fr)
Inventor
Sehgal Ashish
Vallabhabhai Patel Bhavesh
Patel Aditya
Kumar Mandal Jayanta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intas Pharmaceuticals Ltd
Original Assignee
Intas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Ltd filed Critical Intas Pharmaceuticals Ltd
Publication of EP2240158A2 publication Critical patent/EP2240158A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • the present invention relates to stabilized injectable formulation of pregabalin and the process of preparing it.
  • This injectable formulation is administered intravenously to the patient requiring Pregabalin treatment.
  • Pregabalin was first disclosed in US patent no. 5,563,175 by Richard B. Silverman et al of the Northwestern University for the treatment of seizure disorder. Chemically Pregabalin is (S)-(+)-3-aminomethyl-5-methyl hexanoic acids.
  • Pregabalin is a structural analogue of, but functionally unrelated to, the naturally occurring transmitter GABA (gamma-aminobutyric acid).
  • GABA gamma-aminobutyric acid
  • Pregabalin acts by binding to the al ⁇ ha-2-delta subunit of voltage-gated calcium channels and is related to the endogenous inhibitory neurotransmitter gamma-aminobutyric acid (GABA), which is involved in the regulation of brain neuronal activity.
  • Pregabalin has been approved for the treatment of diabetic peripheral neuropathy, postherpetic neuralgia, and as an adjunctive treatment for partial onset seizures in adults.
  • Pregabalin is claimed to be used for treating pain which can be related to any of inflammatory, neuropathic, cancer, postoperative pain etc.
  • Pregabalin is thought to be useful for treating physiological conditions associated with psychomotor stimulants, inflammation, gastrointestinal damage, alcoholism, insomnia, and various psychiatric disorders, including mania and bipolar disorder.
  • Pregabalin is marketed by Pfizer in United States of America under the brand name of Lyrica in capsule dosage form in various strengths from 25mg to 300mg. Lyrica capsules are immediate release formulation and are administered to the patients two or three times daily.
  • PCT patent application no. WO2007052125 discloses matrix oral dosage form of pregabalin suitable for once a day administration whereas another PCT patent application no. WO2005063229 describes an oral liquid composition of Pregabalin.
  • injectable dosage form of pregabalin is still not reported. Injectable dosage form has its own advantage compared to other dosage forms. Injectable dosage forms provides quick onset of drug action compared to those administered orally. Also the therapeutic response of a drug is more readily controlled by injectable administration since the irregularities of intestinal absorption after oral administration of drag are circumvented.
  • Injectable dosage forms are normally administered by a professionally trained person, so it is expected that the dose is actually and accurately administered. Additionally when the patient is uncooperative or unconscious, it becomes difficult to administer the drug orally to the patient. In this case, an injectable dosage form is best suited for administration.
  • the inventors of the present invention have prepared an injectable dosage form of Pregabalin which is stable and well suited for administration to a patient.
  • the injectable formulation is administered intravenously, so the drug directly reaches into the bloodstream via a vein. This causes quick onset of drug action and the therapeutic effect is achieved much quicker.
  • the main object of the invention is to formulate an injectable dosage form of Pregabalin which is administered through intravenous, intramuscular, subcutaneous route or through infusion, preferably through intravenous route to a patient.
  • Additional object of the invention is to formulate iso-osmotic injectable dosage form of pregabalin.
  • One more object of the invention is to provide a process to formulate a stable injectable formulation of pregabalin using normal equipment for preparing injectable formulations.
  • the present invention provides a stable injectable formulation of pregabalin. Further, the present invention describes a process for the preparation of the said stable injectable formulation of pregabalin.
  • Formulating an injectable dosage form has many challenges compared to other dosage forms. As the drug is directly administered to blood circulation, it is essential that the formulation should be of high quality and should provide maximum safety to the patient. Choice of excipients and their quality is a critical factor in formulating an injectable dosage form.
  • the drug for present invention (Pregabalin) is susceptible to oxidation. Other challenges are with respect to the stability of the formulation. By maintaining a suitable pH condition Pregabalin injectable formulation remains stable. Considering these, the inventor of the present invention has formulated an injectable formulation of pregabalin which is stable and well suited for intravenous administration to a patient. It may also be diluted in commonly used intravenous fluids for infusion administration thereby allowing the drug to be administered with greater regularity in order to obtain a more precise and safer effect.
  • the injection prepared according to the present invention is a clear colourless solution. So any foreign particles, such as glass residues, fibers, undissolved substances and the like, inside the ampoule or vials is well controlled. This is particularly required while formulating an intravenous injection.
  • the formulation of the present invention apart from the active pharmaceutical ingredient comprises of pharmaceutically acceptable excipients like vehicle, tonicity adjusting agent, buffering agent, anti-oxidants, pH adjusting agent and other excipients suitable to be used for an intravenous injection.
  • Vehicles are inert and non-toxic substances having no therapeutic activity. These are administered to provide an effective dose of the active ingredient. They present to body tissues the form of the active ingredient for absorption.
  • Vehicles used in the present formulation can be selected from aqueous vehicle, water miscible vehicle and nonaqueous vehicle.
  • Aqueous vehicle can be water whereas water miscible vehicles are solvents miscible with water.
  • the water miscible vehicles can be ethyl alcohol, polyethylene glycol, propylene glycol and the likes.
  • Non-aqueous vehicles can be fixed oils.
  • the preferred vehicle used in the formulation of present invention is water for injection (WFI).
  • An intravenous injection is required to be isotonic with body fluids.
  • isotonic means that the formulation has essentially the same osmotic pressure as human blood.
  • tonicity adjusting agent or tonicity modifiers are used.
  • Tonicity modifiers suitable for this invention include salts and amino acids.
  • the preferred tonicity modifier used is sodium chloride. Desired tonicity of the formulation is between 200 to 400, more preferably the desired tonicity of the formulation is 300.
  • Stability of the formulation of present invention is pH dependent. During the manufacturing process, the pH of the formulation of present invention is essentially maintained at a range of 5.8 to 6.2, preferably at pH 6.0. This enhances the stability of the injectable formulation.
  • a pH adjusting agent is used which can be acid or base.
  • the base can be oxides, hydroxides, carbonates, bicarbonates and the likes.
  • the oxides can be metal oxides such as calcium oxide, magnesium oxide and the likes; hydroxides can be of alkali metals and alkaline earth metals such as sodium hydroxide, potassium hydroxide, calcium hydroxide and the likes and carbonates can be sodium carbonate, sodium bicarbonates, potassium bicarbonates and the likes.
  • the acid can be mineral acid and organic acids such as hydrochloric acid, nitric acid, phosphoric acid, acetic acid, citric acid, fumaric acid, malic acid tartaric acid and the likes.
  • the preferred base and acid used in the formulation of present invention for pH adjustment are sodium hydroxide and hydrochloric acid respectively.
  • a buffering agent is also used in the formulation of present invention to stabilize the formulation against chemical degradation that might occur due to pH drift.
  • the buffering agents used in the formulation of present invention can be citrates, acetates, phosphates other organic buffers and the likes.
  • the preferred buffering agent used in present case is citric acid monohydrate.
  • Pregabalin is susceptible to oxidation and to prevent this, an antioxidant is used in the formulation.
  • An antioxidant is a molecule capable of slowing or preventing the oxidation of other molecules. Oxidation is a chemical reaction that transfers electrons from a substance to an oxidizing agent. Oxidation reactions can produce free radicals, which start chain reactions that can have adverse effect on the purity and stability of the formulation. Antioxidants terminate these chain reactions by removing free radical . intermediates, and inhibit other oxidation reactions by being oxidized themselves.
  • Sulfites like sodium sulfite, sodium bisulfite, sodium metabisulfite, sodium formaldehyde sulfoxylate, thiourea, sequestering agents such as sodium salt of ethylenediaminetetraacetic acid (EDTA) and acids such as citric acid and the likes can be used as antioxidant.
  • EDTA ethylenediaminetetraacetic acid
  • the process for the preparation of injectable pregabalin formulation according to the present inventions comprises the steps of:
  • Nitrogen sparging helps in removing dissolved oxygen from the solution and hence minimizes oxidative degradation of oxidation susceptible drugs.
  • the injectable pregabalin formulation is stable at pH between 4.0 to 8.0, more preferably between pH 5.0 to 7.0.
  • the process of preparation of formulation of the present invention does not require any particular or sophisticated apparatus. It is sufficient to use normal equipments to prepare the pharmaceutical formulations of present invention for injectable use.
  • Process of preparation comprise of following steps:
  • the pH was adjusted in the range of 5.8 - 6.2 preferably at 6.0 with IN sodium hydroxide solution and / or hydrochloric acid solution.
  • Pregabalin was then added and dissolved with continuous nitrogen sparging. If required the pH was adjusted to 6.0 (in the range of range 5.8 - 6.2) with IN sodium hydroxide solution and / or hydrochloric acid.
  • PVDF polyvinylfluoridine
  • This formulation can be prepared by following the process mentioned in the earlier example.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP08869815A 2007-12-28 2008-12-26 Stabilisierte injizierbare pregabalin-formulierung Withdrawn EP2240158A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2596MU2007 2007-12-28
PCT/IN2008/000869 WO2009087682A2 (en) 2007-12-28 2008-12-26 Stabilized injectable formulation of pregabalin

Publications (1)

Publication Number Publication Date
EP2240158A2 true EP2240158A2 (de) 2010-10-20

Family

ID=40801860

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08869815A Withdrawn EP2240158A2 (de) 2007-12-28 2008-12-26 Stabilisierte injizierbare pregabalin-formulierung

Country Status (2)

Country Link
EP (1) EP2240158A2 (de)
WO (1) WO2009087682A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498611B (zh) * 2019-01-15 2020-09-01 张惊宇 一种治疗糖尿病周围神经痛的药物及其用途
DK3946260T3 (da) * 2019-03-26 2026-03-23 Orion Corp Pregabalinformuleringer og anvendelse deraf
WO2022043227A1 (en) * 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
CN113069411B (zh) * 2021-04-02 2022-08-09 石家庄四药有限公司 一种己酮可可碱注射液及其制备方法
WO2022256545A1 (en) * 2021-06-04 2022-12-08 Nevakar Injectables Inc. Injectable pregabalin formulations
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
GB2624861A (en) 2022-11-28 2024-06-05 Orbit Pharma Ltd Sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof
GB2639602A (en) 2024-03-19 2025-10-01 Novumgen Ltd An orodispersible tablet of pregabalin and its process of preparation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP980342A2 (en) * 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
EP1977745B1 (de) * 1999-04-08 2010-04-07 Warner-Lambert Company LLC Behandlung von Inkontinenz
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1471909A4 (de) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc Pharmazeutische zusammensetzung und verfahren zur behandlung von erkrankungen des zentralen nervensystems
KR20060119971A (ko) * 2003-09-11 2006-11-24 제노포트 인코포레이티드 Ｇａｂａ 유사체의 전구약물을 이용한 요실금의 치료및/또는 예방
US7488846B2 (en) * 2005-04-11 2009-02-10 Teva Pharmaceuical Industries Ltd. Pregabalin free of lactam and a process for preparation thereof
EP1992609A1 (de) * 2007-05-14 2008-11-19 Dipharma Francis S.r.l. Verfahren für die Herstellung einer (S)(+)-3-(Aminomethyl)-5-Methylhexan-Säure

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009087682A3 *

Also Published As

Publication number Publication date
WO2009087682A2 (en) 2009-07-16
WO2009087682A3 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
WO2009087682A2 (en) Stabilized injectable formulation of pregabalin
JP2572768B2 (ja) レボドパメチルエステルを有効成分とするパ−キンソン病治療剤
KR100730502B1 (ko) 약제학적 트라마돌 염 및 이를 함유하는 투여 제형
ES2432666T3 (es) Suspensión pediátrica estabilizada de carisbamato
JP2004534764A (ja) 液状医薬組成物
US20050171203A1 (en) Pregabalin composition
JP2012515154A (ja) 鎮痛分子及び／または鎮痙分子を経口経粘膜投与するための処方物
US20130109729A1 (en) Pharmaceutical composition
WO2020039262A1 (en) Pharmaceuticals solution for oral dosage
WO2015144825A1 (en) Oral liquid pharmaceutical solution of gabapentin
US20250302779A1 (en) Stable aqueous hydroxycarbamide solution
US20080138383A1 (en) Compositions and methods for treating seizures
RS61749B1 (sr) Rastvor levodope za infuziju
JP2007508313A (ja) メチルフェニデート溶液および関連する投与および製造方法
JP2022511673A (ja) 運動障害を処置するためのガボキサドール、ガナキソロンおよびアロプレグナノロンの使用
WO2004098614A1 (ja) メチルコバラミン含有凍結乾燥製剤及びその製造方法
CN1617719A (zh) 包含p－gp抑制剂和抗癫痫药物的组合
US20150272872A1 (en) Oromucosal Apomorphine Compositions
MX2013012827A (es) Composicion oral liquida que comprende sodio divalproex y proceso para la preparar la misma.
WO2021231582A1 (en) Nitro-aminoadamantane compounds for the treatment of negative symptoms and cognitive impairment associated with schizophrenia
CN114466683A (zh) 治疗方法及其用途
KR20170099911A (ko) 파라세타몰 주사 제제
EP2905020A1 (de) Brauseformulierungen mit Ibuprofen und N-Acetylcystein
RU2071772C1 (ru) Лекарственное средство для лечения рассеянного склероза
JP6935930B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100728

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150701